Thursday, February 22, 2024

Intego Clinical Scientists Accepted to Present on Generative AI and Statistical Programming Challenges in the Pharmaceutical Industry at PHUSE US Connect 2024

Bethesda, Md. (February 22, 2024) – Intego Clinical, a full-service biometrics Clinical Research Organization (CRO) that helps leading life science companies unlock the power of clinical data, has been accepted to provide three presentations and papers at this year’s PHUSE US Connect – the clinical data science conference – at the Bethesda North Marriott Hotel & Conference Center taking place February 25-28, 2024.

Presentations and papers from Intego Clinical biometrics experts at this year’s clinical data science event include:

  • Navigating the Safe Integration of AI (ChatGPT) into Clinical Trial Programming Workflow,” presented by Senior Statistical Programmer Mykyta Vysotskyi.
  • Risk-Based Monitoring Using AI/ML Detection of Systematic Bias in Clinical Data,” presented by Lead Data Scientist Kostiantyn Drach and CEO Sergey Glushakov in the PHUSE/FDA Innovation Challenge.
  • It is Time to Get Answers: Handling of Questionnaire Data in Respiratory Studies,” presented by Senior Statistical Programmer Valeriia Oreshko.

“It is incredibly satisfying to see the biometrics team have the ability to display our AI, machine learning, and clinical data science knowledge in such a public forum, as we do on a daily basis for a number of the world’s largest pharmaceutical companies,” said Glushakov. “Innovation is in our company’s DNA. It is our mission to leverage data science to spark clinical breakthroughs and we are proud to have the opportunity to showcase these innovations through plenary sessions and the FDA Innovation Challenge.”

AI is changing the future of pharma

Expected to change the industry’s future, artificial intelligence (AI) in the pharmaceutical industry is expected to grow at a compound annual growth rate of nearly 43 percent, exceeding USD 18 billion market by 2029 according to a recent report from Mordor Intelligence.

Understanding this, Intego Clinical has been exploring and facilitating the use of AI and machine learning in the pharmaceutical industry for years, as evidenced by its 2022 win of the PHUSE/FDA Innovation Challenge for its novel approach involving the pure geometric properties within datasets to reveal hidden patterns through graph-based machine learning algorithms.

Glushakov continued, “Through this and our tailored FSP staff augmentation, unit-based, or full-service engagement, Intego Clinical has been on the leading edge of these projected growth patterns, seeing as much as 20 percent growth annually since inception and maintaining the largest number of clinical data professionals in Eastern Europe.”

Seen as a tier one FSP partner, Intego Clinical supports several of top 10 pharmaceutical companies in the following areas:

  • Statistical Programming
  • Data Management
  • Biostatistics
  • Software Engineering
  • CDISC Migration

To join us on-site at PHUSE US Connect 2024, register for Intego Clinical’s pre-conference Tee-off at PHUSE event here:

For those unable to attend the event, learn more about Intego Clinical’s leadership in biometrics here:

About Intego Clinical

Intego Clinical is a biometrics Clinical Research Organization (CRO) that helps leading life science companies unlock the power of clinical data. Its team of data science professionals has substantial experience in the regulatory, statistical, and data management spaces operating across a broad range of therapeutic areas along the entire drug development pipeline. With a focus on transparent and flexible engagement models, Intego Clinical is an effective and efficient full-service CRO with a global team of experts across four key locations in North and Central America, Poland, and the Ukraine.

Learn more at

Media Contact

Don F. McLean, McLean Media


Stay in touch

Get connected with Intego, and let us know how we can help.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intego Insights